Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BB-1705 in Advanced Solid Tumors
NCT05217693Phase 1Recruiting
- Sponsor
- Bliss Biopharmaceutical
- Start
- Jun 2022
- Primary completion
- Jun 2025
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of BB-1705 in solid tumor (2 arms), sponsored by Bliss Biopharmaceutical. Primary endpoints: Number of subjects with adverse events and serious adverse events up to 2 years, Number of subjects with dose limiting toxicity and 1 more. Started Jun 2022; status: recruiting.
02
Drugs
BB-1705
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT05217693.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05217693.